Refined R&D Indicators for Pharmaceutical Industry

  • Mari Jibu
  • Yoshiyuki Osabe
Part of the Lecture Notes in Electrical Engineering book series (LNEE, volume 309)


For the sake of providing evidences that contribute to policy making or strategy planning in pharmaceutical industry, we tried to create new R&D indicators to foresight the picture of pharmaceutical industries. We found that R&D pipelines can be good drug-R&D-indicator. We also show new drug-patent-indicators for identifying patents related with pharmaceutical entities’ R&D progress (”Pre-clinical” → ”Phase 1” → ”Phase 2” → ”Phase 3”→ ”Filed ”→ ”Approved” → ”Marketed”). IPC Count, forward citations, and Citations to Non-Patent Literature are found as new drug-patent-indicators. Not only R&D pipelines but also patents extracted by new drug-patent-indicators are considered to foresight pharmaceutical industries’ potential of creating new drugs.


Pharmaceuticals Patents Indicators Research and development Small molecules Bio-medicine Biotechnology Evidence-based policy patent quality 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    OECD Pharmaceutical Pricing Policies in a Global Market 216 (2008)Google Scholar
  2. 2.
    Mihara, K.: Considerations on patent valuation based on patent classification and citation in biotechnological field. Johokanri 54(11), 738–749 (2012)Google Scholar
  3. 3.
    OECD “Working Party on Industry Analysis Measuring patent ‘quality’: refined indicators for cross-country evidence” (2012) DSTI/EAS/IND/WPIA(2012)6Google Scholar
  4. 4.
    Goto, A., Genba, K., Suzuki, J., Tamada, S.: RIETEI Discussion Paper Series 6-J-018 (2006) (in Japanese)Google Scholar
  5. 5.
    Caviggioli, F., Schellato, G., Ughetto, E.: Understanding patent quality: evidence from patent opposition cases at the European Patent Office,'Understanding+patent+quality%3A+evidence+from+patent+opposition+cases+at+the+European+Patent+Office' (accessed October 25, 2011)
  6. 6.
    Trajtenbert, M.: A Penny for Your Quotes: Patent Citations and the Value of Innovation. RAND Journal of Economics 21(1), 172–187 (1990)CrossRefGoogle Scholar
  7. 7.
    Narin, F., Hamilton, K.S., Olivastro, D.: The increasing linkage between U.S. technology and public science. Research Policy 26, 317–330 (1997)CrossRefGoogle Scholar
  8. 8.
    Callaert, J., Van Looy, B., Verbeek, A., Debackere, K., Thijs, B.: Traces of Prior Art: An Analysis of Non-patent References found in Patent Documents. Scientometrics 69(1), 3–20 (2006)CrossRefGoogle Scholar
  9. 9.
    Cassiman, B., Vaugelers, R., Zuniga, P.: In search of performance effects of (in)direct industry science links. Industrial and Corporate Change 17(4), 611–646 (2008)CrossRefGoogle Scholar
  10. 10.
    Branstetter, L.: Exploring the Link Between Academic Science and Industrial Innovation. Annals of Economic and Statistics 79/80, 119–142 (2005)Google Scholar
  11. 11.
    OECD: Science, Technology and Industry Scoreboard, 1–275 (2013)Google Scholar
  12. 12.
    Osabe, Y., Jibu, M.: Development of new indicators for the launch of a Japanese version of NIH (1). Johokanri 56(7), 448–458 (2013) (in Japanese) Google Scholar
  13. 13.
    Osabe, Y., Jibu, M.: Development of new indicators for the launch of a Japanese version of NIH (2). Johokanri 56(9) (2013) (in press & in Japanese) Google Scholar
  14. 14.
    Osabe, Y., Jibu, M.: Development of new indicators for the launch of a Japanese version of NIH (3). Johokanri 56(10) (2014) (in press & in Japanese)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.The Organisation for Economic Co-operation and Development(OECD)Paris, CEDEX 16France
  2. 2.Japan Science and Technology AgencyChiyoda-kuJapan
  3. 3.Japan Patent OfficeChiyoda-kuJapan
  4. 4.Institute for Technology, Enterprise and CompetitivenessDoshisha UniversityKyotoJapan

Personalised recommendations